CD44V6在非小细胞肺癌中的表达及其预后意义

Expression of CD44V6 in non small cell lung carcinoma and its significance in prognosis

应用免疫组化Ｓ－Ｐ方法对６２例有５５年随访资料的非小细胞肺癌（ＮＳＣＬＣ）组织进行ＣＤ４４Ｖ６的检测，以探讨其在ＮＳＣＬＣ组织中的表达及其预后的意义。测得ＮＳＣＬＣ的ＣＤ４４Ｖ６阳性表达率为６９．３％，和组织分型无明显相关；ＣＤ４４Ｖ６阳性表达和ＮＳＣＬＣ的临床分期、淋巴结转移以及３年、５年术后生存率有关（Ｐ＜０．００５～０．０５）。结果还表明ＣＤ４４Ｖ６强阳性表达者均为＞６ｃｍ的肺癌。提示ＣＤ４４Ｖ６表达强度和肿瘤大小有关。ＮＳＣＬＣ中，ＣＤ４４Ｖ６阳性表达者容易发生淋巴结转移，预后较差。上述结果表明。

To study the expression of CD44V6 in non small cell lung carcinoma(NSCLC) and the correlation between CD44V6 positive expression and prognosis,tissue sections from 62 cases with NSCLC who had been followed up for five years were investigated for expression of CD44V6 by immunohistochemistry(S P method).The results showed that the expression rate of CD44V6 in NSCLC was 69.3%,and CD44V6 positive expression was associated with clinical stages lymphnode metastasis and 3 and 5 year survival rate of postoperation but was not correlated with histologic types.In addition,strong positive expression of CD44V6 was seen in the patients with tumor size above 6 cm.The results suggest that CD44V6 positive expression might be used as an indicator for the development of prognosis in NSCLC.Therefore,CD44V6 is considered as one of the examinations for evaluating the progress of lung carcinoma.